Electromed, Inc. (ELMD) is a Healthcare stock trading at $40.23 (as of 2026-08-20), with a market capitalization of $333.11M and a trailing P/E of 34.0. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products primarily to home health care market for patients with bronchiectasis, cystic fibrosis, and neuromuscular disease. Electromed, Inc. markets its products primarily to physicians and health care providers, as well as directly to patients. The company was incorporated in 1992 and is headquartered in New Prague, Minnesota.
Electromed develops, manufactures, markets, and sells airway clearance therapy products (SmartVest system, related SQL components, and SmartVest Connect wireless therapy management) that generate revenue primarily from Homecare sales to patients in the United States and internationally.
Profitability is closely tied to Homecare revenue, which depends on the size of the direct field sales team and the share of Covered Lives Under Contract United States.
| Homecare | $0.0B |
| Non-Homecare | $0.0B |
Business quality (Solid): Most operating visibility comes from Homecare-related metrics, while non-homecare and international/institutional revenue are shown as 0.0B for the latest quarter, suggesting limited disclosure or concentration in one area.
Valuation: At 32× earnings, ELMD trades in line with the Medical Equipment average (32×). Note: one-time items can distort reported P/E.
| Price | $40.23 |
| Market Cap | $333.11M |
| P/E Ratio | 34.0 |
| EV / EBITDA | 22.4 |
| Price / Book | 6.78 |
| Price / Sales | 4.76 |
| FCF Yield | 4.6% |
| DCF Value (model) | $16.41 |
| DCF Upside vs Price | -59.2% |
| Revenue (TTM) | $64.00M |
| Net Margin | 11.8% |
| Revenue Growth (YoY) | 18.4% |
| EPS Growth (YoY) | 68.2% |
| FCF Growth (YoY) | -24.0% |
| Altman Z-Score | 22.13 (safe) |
| Stock P/E | 34.0 |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Medical Equipment) | 32.9 |
| vs Sector | 57.5% |
| vs Industry | 3.5% |
| Top Institutional Holder | VANGUARD GROUP INC ($13.02M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Medical Equipment |
| CEO | James L. Cunniff |
| Employees | 174 |
| Country | US |
| IPO Date | 2010-08-13 |
Data as of 2026-08-20.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.